2025 IMF Nurse Leadership Board Annual Meeting Read more about 2025 IMF Nurse Leadership Board Annual Meeting Add new comment
December 2025 – Myeloma News from the Journals Read more about December 2025 – Myeloma News from the JournalsAdd new comment
U.S. FDA Awards National Priority Voucher to sBLA Application for Tecvayli and Darzalex Faspro Combination Based on MajesTEC-3 Trial Results Read more about U.S. FDA Awards National Priority Voucher to sBLA Application for Tecvayli and Darzalex Faspro Combination Based on MajesTEC-3 Trial ResultsAdd new comment
U.S. FDA Grants Breakthrough Therapy Designation for Tecvayli plus Darzalex Faspro as a Second Line for Patients with Relapsed/Refractory Multiple Myeloma Read more about U.S. FDA Grants Breakthrough Therapy Designation for Tecvayli plus Darzalex Faspro as a Second Line for Patients with Relapsed/Refractory Multiple MyelomaAdd new comment
IMF Medical Student Scholar for Health Equity in Myeloma Abena Prempeh Receives Prestigious 2025 ASH Abstract Achievement Award Read more about IMF Medical Student Scholar for Health Equity in Myeloma Abena Prempeh Receives Prestigious 2025 ASH Abstract Achievement Award Add new comment
2025 IMF Brian D. Novis Research Grants Read more about 2025 IMF Brian D. Novis Research Grants Add new comment
November 2025 – Myeloma News from the Journals Read more about November 2025 – Myeloma News from the JournalsAdd new comment
35 Years of Defying Boundaries and Redefining Possibilities Read more about 35 Years of Defying Boundaries and Redefining Possibilities Add new comment
US FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for High-Risk Smoldering Multiple Myeloma Read more about US FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for High-Risk Smoldering Multiple MyelomaAdd new comment
